Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
The purpose of this study is to assess whether SCH 900435 (Org 25935) 16 mg twice daily is more effective than placebo in the treatment of patients with schizophrenia, using olanzapine 15 mg once daily as active control.
Epistemonikos ID: 4cfd34be3410610e775b355d8506a9480b147db6
First added on: May 05, 2024